Iovance Biotherapeutics
David Wieand has an extensive background in clinical operations and leadership development. With experience in managing clinical trials, overseeing patient experience solutions, and coaching and developing teams, David brings a wealth of knowledge and expertise to their current roles at Iovance Biotherapeutics, Inc. and DJW & Associates. David also has a strong foundation in social work and basic science research, making him a well-rounded professional in the healthcare industry.
This person is not in the org chart
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.